Norden Group LLC Buys New Holdings in DexCom, Inc. (NASDAQ:DXCM)

Norden Group LLC purchased a new position in shares of DexCom, Inc. (NASDAQ:DXCM) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 16,058 shares of the medical device company’s stock, valued at approximately $2,227,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. State of Alaska Department of Revenue boosted its position in shares of DexCom by 0.3% during the 1st quarter. State of Alaska Department of Revenue now owns 41,830 shares of the medical device company’s stock valued at $5,801,000 after acquiring an additional 105 shares in the last quarter. Allspring Global Investments Holdings LLC lifted its stake in DexCom by 0.3% during the first quarter. Allspring Global Investments Holdings LLC now owns 1,288,758 shares of the medical device company’s stock worth $178,751,000 after purchasing an additional 4,193 shares during the period. Vaughan Nelson Investment Management L.P. boosted its holdings in DexCom by 21.3% during the first quarter. Vaughan Nelson Investment Management L.P. now owns 1,413,958 shares of the medical device company’s stock valued at $196,117,000 after purchasing an additional 248,111 shares in the last quarter. Congress Wealth Management LLC DE grew its stake in shares of DexCom by 0.6% in the 1st quarter. Congress Wealth Management LLC DE now owns 168,657 shares of the medical device company’s stock valued at $23,393,000 after purchasing an additional 952 shares during the period. Finally, Trilogy Capital Inc. acquired a new position in shares of DexCom in the 1st quarter worth approximately $470,000. Institutional investors own 97.75% of the company’s stock.

DexCom Price Performance

DXCM opened at $110.91 on Friday. The company has a fifty day moving average price of $121.24 and a two-hundred day moving average price of $125.37. The company has a debt-to-equity ratio of 1.08, a quick ratio of 2.53 and a current ratio of 2.90. The firm has a market capitalization of $44.11 billion, a PE ratio of 71.56, a P/E/G ratio of 2.75 and a beta of 1.16. DexCom, Inc. has a 52 week low of $74.75 and a 52 week high of $142.00.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings data on Thursday, April 25th. The medical device company reported $0.32 EPS for the quarter, topping analysts’ consensus estimates of $0.27 by $0.05. DexCom had a return on equity of 31.01% and a net margin of 16.82%. The business had revenue of $921.00 million during the quarter, compared to analysts’ expectations of $911.20 million. As a group, analysts anticipate that DexCom, Inc. will post 1.78 earnings per share for the current year.

Insider Activity at DexCom

In related news, Director Bridgette P. Heller sold 1,000 shares of the business’s stock in a transaction that occurred on Friday, June 14th. The shares were sold at an average price of $113.55, for a total transaction of $113,550.00. Following the completion of the transaction, the director now owns 25,349 shares in the company, valued at $2,878,378.95. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other news, CEO Kevin R. Sayer sold 49,633 shares of DexCom stock in a transaction dated Monday, April 8th. The stock was sold at an average price of $138.30, for a total transaction of $6,864,243.90. Following the transaction, the chief executive officer now owns 283,893 shares in the company, valued at approximately $39,262,401.90. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Bridgette P. Heller sold 1,000 shares of the stock in a transaction that occurred on Friday, June 14th. The stock was sold at an average price of $113.55, for a total value of $113,550.00. Following the sale, the director now directly owns 25,349 shares of the company’s stock, valued at $2,878,378.95. The disclosure for this sale can be found here. Insiders have sold 55,735 shares of company stock worth $7,619,347 in the last ninety days. Company insiders own 0.30% of the company’s stock.

Analysts Set New Price Targets

Several analysts recently commented on DXCM shares. StockNews.com lowered DexCom from a “buy” rating to a “hold” rating in a research note on Monday, June 10th. UBS Group boosted their target price on shares of DexCom from $153.00 to $163.00 and gave the company a “buy” rating in a research note on Wednesday, April 10th. Raymond James lifted their price target on shares of DexCom from $151.00 to $160.00 and gave the company a “strong-buy” rating in a report on Friday, April 26th. Canaccord Genuity Group upped their price objective on shares of DexCom from $144.00 to $145.00 and gave the stock a “buy” rating in a research note on Friday, April 26th. Finally, Royal Bank of Canada initiated coverage on DexCom in a research report on Tuesday, March 12th. They set an “outperform” rating and a $165.00 price target on the stock. Four investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, DexCom presently has a consensus rating of “Moderate Buy” and a consensus target price of $140.33.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.